PBI 05204 - Phoenix Biotechnology

Drug Profile

PBI 05204 - Phoenix Biotechnology

Alternative Names: Oleandrin - Phoenix Biotechnology; PBI-05204

Latest Information Update: 05 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Phoenix Biotechnology; United States Army Medical Research Institute of Infectious Diseases
  • Class Antineoplastics; Cardenolides
  • Mechanism of Action Apoptosis stimulants; Fibroblast growth factor inhibitors; NF-kappa B inhibitors; Proto oncogene protein c-akt inhibitors; Transcription factor AP-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer
  • Preclinical Viral infections
  • No development reported Stroke

Most Recent Events

  • 13 Sep 2017 Preclinical trials in Viral infections in USA (unspecified route) before September 2017
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Stroke in USA (PO, Capsule)
  • 01 Apr 2015 Phase-II clinical trials in Pancreatic cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT02329717)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top